{"transactions":[{"id":1036130,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Restricted Stock Units","published_at":"2025-09-18T21:09:41.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15900,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Performance-Based RSUs (\"PRSUs\") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each PRSU represents a contingent right to receive one share of Common Stock on the vesting dates of the PRSU."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."},{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15900},"source":{"system":"sec-edgar","filing":"0001585839-25-000004","document":"form4-09192025_010937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000158583925000004/form4-09192025_010937.xml","form_type":"4"}},{"id":1036129,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Restricted Stock Units","published_at":"2025-09-18T21:09:41.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15900,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Performance-Based RSUs (\"PRSUs\") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each PRSU represents a contingent right to receive one share of Common Stock on the vesting dates of the PRSU."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."},{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15900},"source":{"system":"sec-edgar","filing":"0001585839-25-000004","document":"form4-09192025_010937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000158583925000004/form4-09192025_010937.xml","form_type":"4"}},{"id":1036128,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:09:41.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":6.16,"expiration_date":"2035-01-17","underlying":"Common Stock","underlying_shares":63500},"source":{"system":"sec-edgar","filing":"0001585839-25-000004","document":"form4-09192025_010937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000158583925000004/form4-09192025_010937.xml","form_type":"4"}},{"id":1036127,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T21:09:41.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":170000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.47,"expiration_date":"2034-07-12","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001585839-25-000004","document":"form4-09192025_010937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000158583925000004/form4-09192025_010937.xml","form_type":"4"}},{"id":1036126,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-09-18T21:09:41.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":77800,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the \"Effective Time\"), pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001585839-25-000004","document":"form4-09192025_010937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000158583925000004/form4-09192025_010937.xml","form_type":"4"}},{"id":1297249,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-22T19:05:55.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":63500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2026, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":63500,"derivative":{"exercise_price":6.16,"expiration_date":"2035-01-17","underlying":"Common Stock","underlying_shares":63500},"source":{"system":"sec-edgar","filing":"0001415889-25-001879","document":"form4-01232025_120151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000141588925001879/form4-01232025_120151.xml","form_type":"4"}},{"id":1297248,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-01-22T19:05:55.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":31800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2026, January 17, 2027 and January 17, 2028, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":77800,"source":{"system":"sec-edgar","filing":"0001415889-25-001879","document":"form4-01232025_120151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000141588925001879/form4-01232025_120151.xml","form_type":"4"}},{"id":1455167,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-07-12T17:29:54.000Z","date":"2024-07-12","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options shall vest and become exercisable as to 25% of the shares subject to the option on July 12, 2025, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":170000,"derivative":{"exercise_price":12.47,"expiration_date":"2034-07-12","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001415889-24-019529","document":"form4-07122024_090750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000141588924019529/form4-07122024_090750.xml","form_type":"4"}},{"id":1455166,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2024-07-12T17:29:54.000Z","date":"2024-07-12","kind":"grant","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSU. The RSUs vest by 1/3 on each of July 12, 2025, July 12, 2026 and July 12, 2027, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":46000,"source":{"system":"sec-edgar","filing":"0001415889-24-019529","document":"form4-07122024_090750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000141588924019529/form4-07122024_090750.xml","form_type":"4"}},{"id":1625345,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-22T21:32:59.000Z","date":"2024-02-21","kind":"sale","planned":false,"acquired":false,"shares":3764,"price":7.46,"value":28079.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.54, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":175669,"source":{"system":"sec-edgar","filing":"0001104659-24-026556","document":"tm246990-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924026556/tm246990-2_4seq1.xml","form_type":"4"}},{"id":1638198,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:58:45.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service."}],"balance_after":60000,"derivative":{"exercise_price":7.6,"expiration_date":"2034-02-09","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-24-024981","document":"tm246517-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924024981/tm246517-1_4seq1.xml","form_type":"4"}},{"id":1638197,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-16T21:58:45.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service."}],"balance_after":179433,"source":{"system":"sec-edgar","filing":"0001104659-24-024981","document":"tm246517-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924024981/tm246517-1_4seq1.xml","form_type":"4"}},{"id":1764332,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-05T20:41:46.000Z","date":"2023-10-03","kind":"sale","planned":false,"acquired":false,"shares":13567,"price":6.99,"value":94833.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2023. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2023. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.24, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":149433,"source":{"system":"sec-edgar","filing":"0001104659-23-107217","document":"tm2327817-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923107217/tm2327817-1_4seq1.xml","form_type":"4"}},{"id":1999835,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-23T01:55:32.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 17, 2023. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service."}],"balance_after":76000,"derivative":{"exercise_price":7.43,"expiration_date":"2033-02-17","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001104659-23-024422","document":"tm237526-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923024422/tm237526-3_4seq1.xml","form_type":"4"}},{"id":1999834,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-23T01:55:32.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under an aggregate of 38,000 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 17, 2023. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service."}],"balance_after":163000,"source":{"system":"sec-edgar","filing":"0001104659-23-024422","document":"tm237526-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923024422/tm237526-3_4seq1.xml","form_type":"4"}},{"id":2144559,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-04T20:15:31.000Z","date":"2022-10-01","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the \"Company\"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4)."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of shares of common stock underlying a restricted stock unit (\"RSU\") award. Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is October 1, 2022. The RSU award vests over three years, with 33.333% of the shares of common stock underlying the RSU award vesting upon the one-year anniversary of such vesting commencement date and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued service as an employee."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0001104659-22-105844","document":"tm2227394-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922105844/tm2227394-1_4seq1.xml","form_type":"4"}},{"id":2153510,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-21T20:41:21.000Z","date":"2022-09-19","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the \"Company\"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee."}],"balance_after":200000,"derivative":{"exercise_price":6.18,"expiration_date":"2032-09-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-22-101958","document":"tm2226340-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922101958/tm2226340-3_4seq1.xml","form_type":"4"}},{"id":2377310,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-23T16:38:36.000Z","date":"2022-02-22","kind":"sale","acquired":false,"shares":1542,"price":3.529,"value":5441.718,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.76. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":8927,"source":{"system":"sec-edgar","filing":"0001127602-22-006327","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222006327/form4.xml","form_type":"4"}},{"id":2377309,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-23T16:38:36.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":1404,"price":3.877,"value":5443.308,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.79 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":10469,"source":{"system":"sec-edgar","filing":"0001127602-22-006327","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222006327/form4.xml","form_type":"4"}},{"id":2384748,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-18T16:14:31.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units will fully vest on July 4, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units will fully vest on July 4, 2023."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001127602-22-005755","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222005755/form4.xml","form_type":"4"}},{"id":2384747,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-18T16:14:31.000Z","date":"2022-02-17","kind":"sale","acquired":false,"shares":1296,"price":4.2,"value":5443.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.00 to $4.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":11873,"source":{"system":"sec-edgar","filing":"0001127602-22-005755","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222005755/form4.xml","form_type":"4"}},{"id":2384746,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-18T16:14:31.000Z","date":"2022-02-16","kind":"sale","acquired":false,"shares":1229,"price":4.429,"value":5443.241,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.29 to $4.54. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":13169,"source":{"system":"sec-edgar","filing":"0001127602-22-005755","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222005755/form4.xml","form_type":"4"}},{"id":2391270,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-16T16:59:50.000Z","date":"2022-02-14","kind":"exercise","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001127602-22-005327","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222005327/form4.xml","form_type":"4"}},{"id":2391269,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-16T16:59:50.000Z","date":"2022-02-15","kind":"sale","acquired":false,"shares":1347,"price":4.331,"value":5833.857,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.28 to $4.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":14398,"source":{"system":"sec-edgar","filing":"0001127602-22-005327","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222005327/form4.xml","form_type":"4"}},{"id":2391268,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-16T16:59:50.000Z","date":"2022-02-14","kind":"exercise","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 745 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2021."}],"balance_after":15745,"source":{"system":"sec-edgar","filing":"0001127602-22-005327","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760222005327/form4.xml","form_type":"4"}},{"id":2741607,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-04-22T16:22:26.000Z","date":"2021-04-20","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-21-014291","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760221014291/form4.xml","form_type":"4"}},{"id":2903927,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2021-01-19T16:48:50.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025."}],"balance_after":10000,"derivative":{"exercise_price":35.85,"expiration_date":"2031-01-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001127602-21-001981","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760221001981/form4.xml","form_type":"4"}},{"id":2957647,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2020-12-03T17:44:59.000Z","date":"2020-12-02","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% on December 1, 2021 and in equal monthly installments on the same day of each month thereafter and will be fully vested and exercisable on December 1, 2024."}],"balance_after":230000,"derivative":{"exercise_price":27.3,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001127602-20-030495","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585839/000112760220030495/form4.xml","form_type":"4"}},{"id":3005284,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-16T19:41:31.000Z","date":"2020-10-15","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 5,000 ordinary shares.  Under the original terms of the agreement, 33.33% of the RSUs will vest on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.  In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 31, 2020 representing 5,000 ordinary shares.  Under the original terms of the agreement, 33.33% of the RSUs will vest on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.  In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021."}],"balance_after":4000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-20-055037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/doc4.xml","form_type":"4"}},{"id":3005283,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-16T19:41:31.000Z","date":"2020-10-15","kind":"exercise","acquired":false,"shares":2084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted restricted stock units (\"RSUs\") on August 20, 2018 representing 5,000 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.  In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The reporting person was granted restricted stock units (\"RSUs\") on August 20, 2018 representing 5,000 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.  In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021."}],"balance_after":2082,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2084},"source":{"system":"sec-edgar","filing":"0001209191-20-055037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/doc4.xml","form_type":"4"}},{"id":3005282,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-16T19:41:31.000Z","date":"2020-10-15","kind":"exercise","acquired":false,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 5,000 ordinary shares.  33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.  In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 5,000 ordinary shares.  33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.  In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021."}],"balance_after":1667,"derivative":{"underlying":"Ordinary Shares","underlying_shares":833},"source":{"system":"sec-edgar","filing":"0001209191-20-055037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/doc4.xml","form_type":"4"}},{"id":3005281,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-10-16T19:41:31.000Z","date":"2020-10-15","kind":"sale","acquired":false,"shares":1017,"price":21.72,"value":22089.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":10405,"source":{"system":"sec-edgar","filing":"0001209191-20-055037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/doc4.xml","form_type":"4"}},{"id":3005280,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-10-16T19:41:31.000Z","date":"2020-10-15","kind":"sale","acquired":false,"shares":407,"price":21.8243,"value":8882.4901,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":11422,"source":{"system":"sec-edgar","filing":"0001209191-20-055037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/doc4.xml","form_type":"4"}},{"id":3005279,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-10-16T19:41:31.000Z","date":"2020-10-15","kind":"sale","acquired":false,"shares":976,"price":21.7992,"value":21276.0192,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":11829,"source":{"system":"sec-edgar","filing":"0001209191-20-055037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/doc4.xml","form_type":"4"}},{"id":3005278,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-10-16T19:41:31.000Z","date":"2020-10-15","kind":"exercise","acquired":true,"shares":4917,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":12805,"source":{"system":"sec-edgar","filing":"0001209191-20-055037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/doc4.xml","form_type":"4"}},{"id":3042626,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-09-01T18:37:15.000Z","date":"2020-09-01","kind":"exercise","acquired":false,"shares":1042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on August 20, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on August 20, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":4166,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1042},"source":{"system":"sec-edgar","filing":"0001209191-20-048883","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120048883/doc4.xml","form_type":"4"}},{"id":3042625,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-01T18:37:15.000Z","date":"2020-09-01","kind":"sale","acquired":false,"shares":509,"price":22.82,"value":11615.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":7888,"source":{"system":"sec-edgar","filing":"0001209191-20-048883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120048883/doc4.xml","form_type":"4"}},{"id":3042624,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-01T18:37:15.000Z","date":"2020-09-01","kind":"exercise","acquired":true,"shares":1042,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":8397,"source":{"system":"sec-edgar","filing":"0001209191-20-048883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120048883/doc4.xml","form_type":"4"}},{"id":3074843,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-07-28T21:34:11.000Z","date":"2020-07-26","kind":"exercise","acquired":false,"shares":417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs\nvested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs\nvested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":2500,"derivative":{"underlying":"Ordinary Shares","underlying_shares":417},"source":{"system":"sec-edgar","filing":"0001209191-20-043874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120043874/doc4.xml","form_type":"4"}},{"id":3074842,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-28T21:34:11.000Z","date":"2020-07-27","kind":"sale","acquired":false,"shares":141,"price":23.51,"value":3314.91,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":7355,"source":{"system":"sec-edgar","filing":"0001209191-20-043874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120043874/doc4.xml","form_type":"4"}},{"id":3074841,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-28T21:34:11.000Z","date":"2020-07-26","kind":"exercise","acquired":true,"shares":417,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":7496,"source":{"system":"sec-edgar","filing":"0001209191-20-043874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120043874/doc4.xml","form_type":"4"}},{"id":3140873,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-05-20T20:44:38.000Z","date":"2020-05-20","kind":"exercise","acquired":false,"shares":1041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on August 20, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on August 20, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":5208,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1041},"source":{"system":"sec-edgar","filing":"0001209191-20-030900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120030900/doc4.xml","form_type":"4"}},{"id":3140872,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-05-20T20:44:38.000Z","date":"2020-05-20","kind":"sale","acquired":false,"shares":358,"price":25.07,"value":8975.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":7079,"source":{"system":"sec-edgar","filing":"0001209191-20-030900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120030900/doc4.xml","form_type":"4"}},{"id":3140871,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-05-20T20:44:38.000Z","date":"2020-05-20","kind":"exercise","acquired":true,"shares":1041,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":7437,"source":{"system":"sec-edgar","filing":"0001209191-20-030900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120030900/doc4.xml","form_type":"4"}},{"id":3168367,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-04-28T17:51:36.000Z","date":"2020-04-26","kind":"exercise","acquired":false,"shares":417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 5,000 ordinary shares.  33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on January 26, 2019 representing 5,000 ordinary shares.  33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":2917,"derivative":{"underlying":"Ordinary Shares","underlying_shares":417},"source":{"system":"sec-edgar","filing":"0001209191-20-025903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120025903/doc4.xml","form_type":"4"}},{"id":3168366,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-04-28T17:51:36.000Z","date":"2020-04-27","kind":"sale","acquired":false,"shares":141,"price":24.35,"value":3433.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":6396,"source":{"system":"sec-edgar","filing":"0001209191-20-025903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120025903/doc4.xml","form_type":"4"}},{"id":3168365,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-04-28T17:51:36.000Z","date":"2020-04-26","kind":"exercise","acquired":true,"shares":417,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":6537,"source":{"system":"sec-edgar","filing":"0001209191-20-025903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120025903/doc4.xml","form_type":"4"}},{"id":3253030,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-24T21:53:29.000Z","date":"2020-02-20","kind":"exercise","acquired":false,"shares":1042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted restricted stock units (\"RSUs\") on July 19, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The reporting person was granted restricted stock units (\"RSUs\") on July 19, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":6249,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1042},"source":{"system":"sec-edgar","filing":"0001209191-20-012017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120012017/doc4.xml","form_type":"4"}},{"id":3253029,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-24T21:53:29.000Z","date":"2020-02-20","kind":"sale","acquired":false,"shares":360,"price":29.68,"value":10684.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":6120,"source":{"system":"sec-edgar","filing":"0001209191-20-012017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120012017/doc4.xml","form_type":"4"}},{"id":3253028,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-24T21:53:29.000Z","date":"2020-02-20","kind":"exercise","acquired":true,"shares":1042,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amount includes 1,000 shares reported on Reporting Person's Form 3 that were omitted from subsequent Form 4 filings."}],"balance_after":6480,"source":{"system":"sec-edgar","filing":"0001209191-20-012017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120012017/doc4.xml","form_type":"4"}},{"id":3291817,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-04T17:40:22.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date."}],"balance_after":6000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-20-006212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120006212/doc4.xml","form_type":"4"}},{"id":3291816,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock options (right to buy)","published_at":"2020-02-04T17:40:22.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date."}],"balance_after":15000,"derivative":{"exercise_price":29.41,"underlying":"Ordinary Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-006212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120006212/doc4.xml","form_type":"4"}},{"id":3300146,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units (RSUs)","published_at":"2020-01-28T22:15:39.000Z","date":"2020-01-26","kind":"exercise","acquired":false,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 5,000 Restricted Stock Units (\"RSUs\") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted 5,000 Restricted Stock Units (\"RSUs\") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter."}],"balance_after":3334,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001209191-20-005215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120005215/doc4.xml","form_type":"4"}},{"id":3300145,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-01-28T22:15:39.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":667,"price":29.28,"value":19529.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":4438,"source":{"system":"sec-edgar","filing":"0001209191-20-005215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120005215/doc4.xml","form_type":"4"}},{"id":3300144,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-01-28T22:15:39.000Z","date":"2020-01-26","kind":"exercise","acquired":true,"shares":1666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":5105,"source":{"system":"sec-edgar","filing":"0001209191-20-005215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120005215/doc4.xml","form_type":"4"}},{"id":3361225,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-11-22T18:29:33.000Z","date":"2019-11-20","kind":"exercise","acquired":false,"shares":1042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on July 19, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on July 19, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":7291,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1042},"source":{"system":"sec-edgar","filing":"0001209191-19-057753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119057753/doc4.xml","form_type":"4"}},{"id":3361224,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-11-22T18:29:33.000Z","date":"2019-11-20","kind":"sale","acquired":false,"shares":354,"price":28.41,"value":10057.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":3439,"source":{"system":"sec-edgar","filing":"0001209191-19-057753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119057753/doc4.xml","form_type":"4"}},{"id":3361223,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-11-22T18:29:33.000Z","date":"2019-11-20","kind":"exercise","acquired":true,"shares":1042,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":3793,"source":{"system":"sec-edgar","filing":"0001209191-19-057753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119057753/doc4.xml","form_type":"4"}},{"id":3431153,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-08-22T17:31:48.000Z","date":"2019-08-20","kind":"exercise","acquired":false,"shares":4167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on July 19, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs will vest on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted restricted stock units (\"RSUs\") on July 19, 2018 representing 12,500 ordinary shares.  33.33% of the RSUs will vest on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter."}],"balance_after":8333,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001209191-19-047107","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119047107/doc4.xml","form_type":"4"}},{"id":3431152,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-22T17:31:48.000Z","date":"2019-08-20","kind":"sale","acquired":false,"shares":1416,"price":33.07,"value":46827.12,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":2751,"source":{"system":"sec-edgar","filing":"0001209191-19-047107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119047107/doc4.xml","form_type":"4"}},{"id":3431151,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-22T17:31:48.000Z","date":"2019-08-20","kind":"exercise","acquired":true,"shares":4167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":4167,"source":{"system":"sec-edgar","filing":"0001209191-19-047107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119047107/doc4.xml","form_type":"4"}},{"id":3683870,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-01-29T22:25:11.000Z","date":"2019-01-26","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter."}],"balance_after":5000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-005803","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119005803/doc4.xml","form_type":"4"}},{"id":3683869,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-29T22:25:11.000Z","date":"2019-01-26","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter."}],"balance_after":15000,"derivative":{"exercise_price":42.5,"expiration_date":"2029-01-26","underlying":"Ordinary Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-005803","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119005803/doc4.xml","form_type":"4"}},{"id":4062236,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:47:36.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":7.1,"value":1065000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001171843-18-001102","document":"f4_pfreundschuh021318.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001102/f4_pfreundschuh021318.xml","form_type":"4"}},{"id":4062235,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock, Class A","published_at":"2018-02-13T16:47:36.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":263,"price":18,"value":4734.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the \"Merger Agreement\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001171843-18-001102","document":"f4_pfreundschuh021318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001102/f4_pfreundschuh021318.xml","form_type":"4"}},{"id":4100270,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2018-01-12T18:05:33.000Z","date":"2017-12-31","kind":"grant","acquired":true,"shares":263,"price":9.1,"value":2393.3,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":263,"source":{"system":"sec-edgar","filing":"0001171843-18-000353","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318000353/formfour.xml","form_type":"4"}},{"id":4100269,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2018-01-12T18:05:33.000Z","date":"2017-09-30","kind":"grant","acquired":true,"shares":131,"price":9.1,"value":1192.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":131,"source":{"system":"sec-edgar","filing":"0001171843-18-000353","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318000353/formfour.xml","form_type":"4"}},{"id":4374451,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":75195,"kind":"person","name":"PFREUNDSCHUH PETER P.","position":1,"cik":"0001585839","reported_name":"PFREUNDSCHUH PETER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-22T16:02:12.000Z","date":"2017-03-20","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest over a four-year period, with 25% vesting on March 20, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter."}],"balance_after":150000,"derivative":{"exercise_price":10.9,"expiration_date":"2027-03-20","underlying":"Class A Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001171843-17-001686","document":"f4_pfreundschuh032217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317001686/f4_pfreundschuh032217.xml","form_type":"4"}}]}